---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-215683"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2026-05-11T23:59:59+00:00"
generated_at: "2026-05-14T19:01:42.148918+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Apogee reports Q1 loss of $74.1M; $1.3B cash; zumilokibart Phase 3 AD on track

## Summary
- Net loss of $74.1M in Q1 2026 vs. $55.3M a year ago; R&D spend $60.8M, G&A $22.0M.
- Cash, equivalents and securities total $1.3B, up from $902.9M at Dec 2025, aided by $403M equity offering; runway into 2029.
- APEX Part A 52-week data: 75% (3-month) and 85% (6-month) of EASI-75 responders maintained; IGA 0/1 maintained at 86% and 78%.
- APEX Part B 16-week data in AD expected Q2 2026; Phase 3 AD initiation planned H2 2026.
- Positive Phase 1b asthma data shared Jan 2026; asthma and EoE trial details expected later this year.

## SEC filing metadata
- accession: 0001193125-26-215683
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2026-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000119312526215683/0001193125-26-215683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000119312526215683/apge-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-215683
- JSON: https://secwatch.observer/filing/0001193125-26-215683.json
- Plain text: https://secwatch.observer/filing/0001193125-26-215683.txt

## Source-grounded claims
- claim_id: 99bdfa4a2d3e6efff305e554f02893a42a5379c4
  claim: Apogee Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.
  evidence_excerpt: On May 11, 2026, Apogee Therapeutics, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter ended March 31, 2026 (the “Earnings Press Release”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1974640/000119312526215683/0001193125-26-215683-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.